P4‐236: Does concomitant treatment with cholinesterase inhibitors or memantine affect cerebrolysin treatment's efficacy in Alzheimer disease? Results from the Argentinean cerebrolysin registry
| Autor: | Gustavo Albanese, Miryam Bukler, Marta Torres, Marco Tozzola, Mauricio Bosch, Janus Kremer, Galeno Rojas, Gerardo Tiezzi, Alejandro Andersson, Ricardo Klein, Ignacio J. Previgliano, Christiane Ponteville |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Rivastigmine
medicine.medical_specialty biology Epidemiology business.industry Health Policy Memantine medicine.disease Psychiatry and Mental health Cellular and Molecular Neuroscience chemistry.chemical_compound Developmental Neuroscience chemistry Concomitant Cerebrolysin medicine biology.protein Neurology (clinical) Geriatrics and Gerontology Alzheimer's disease business Donepezil Psychiatry Cholinesterase medicine.drug |
| Zdroj: | Alzheimer's & Dementia. 7 |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1016/j.jalz.2011.05.2261 |
| Popis: | O (donepezil) 21 9 0 30 21.16 1.89 I (rivastigmine) 25 9 2 36 17.42 1.73 A (gallantamine) 9 3 0 12 20.66 2 E (memantine) 14 3 1 18 18.10 0.66 OME 40 1 2 43 18.52 3.75 IME 21 9 1 31 15.85 2.26 AME 5 2 0 7 17.83 3 e (cerebrolysin) 20 4 1 25 19.47 4.68 otal 155 40 7 202 18.54 2.76 Diana Pollock, Vikram Atit, George Brewer, Steven Kanzer, Lara Guzman, David Newsome, Ptak Alzheimer’s Research Center, Clearwater, Florida, United States; Atit Neurology Institute, Holiday, Florida, United States; Adeona, Ann Arbor, Michigan, United States. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|